Thursday, November 13, 2025 2:00 PM Eastern Time / 11:00 AM Pacific Time
Presenters:
Professor Srikanth Muppidi, MD – Clinical Professor, Adult Neurology, Stanford Medicine
Naji Gehchan, MD – Chief Medical and Development Officer, Kyverna
Kyverna’s investigational CAR T-cell therapy, KYV-101, is a type of immunotherapy that is different than current treatments for generalized MG (gMG). It is a single dose and works by using a person’s own immune cells to fight disease. During this webinar, we’ll learn more about how CAR T-cell therapies work and discuss an ongoing phase 3 clinical study, called KYSA-6, which is evaluating KYV-101 for patients living with gMG.
Register
After registering, you will receive a confirmation email containing information about joining the webinar.